drugset / Trial / NCT00541775

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

NCT00541775

Phase 3 Completed 273 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.

Timeline

Start
2006-06
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosiglitazone Small molecule 8 mg
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule 1500 mg Oral